BioSpace News Archive

Kite, a Gilead Company (Nasdaq: GILD) and Refuge Biotechnologies, Inc. (“Refuge”), today announced that Kite has entered into an exclusive, worldwide license agreement with Refuge, a synthetic biology company for cancer immunotherapy, for exclusive rights to utilize Refuge’s proprietary gene expression platform to develop potential treatments for blood cancers.

Neonode Inc. (NASDAQ: NEON) is pleased to announce that Elix Systems SA has extended its agreement with Neonode and will increase the use of Neonode’s Touch Sensor Modules to enable touch interaction on displays in medical ultrasound systems.

Endymed Ltd (TASE: ENDY), currently traded on the Tel Aviv Stock Exchange, is proud to announce that it has been granted FDA approval for the marketing and sales of Pure Laser, a new hair removal device in the United States.

Servatus Ltd, an Australian biopharmaceutical company delivering leading, novel autoimmune and microbiome therapies, has begun dosing patients in a world-first human clinical trial studying the effects of using live biotherapeutics to treat the debilitating condition of rheumatoid arthritis (RA).

Spago Nanomedical In accordance with a resolution at Spago Nanomedical AB’s Annual General Meeting on May 18, 2022, a Nomination Committee for the 2023 Annual General Meeting has been appointed.

Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, announced its business update and interim report for January to September 2022.

Harbour BioMed announced that, it has successfully completed the dosing of first patient in the global phase I trial of B7H4x4-1BB bispecific antibody HBM7008 in the United States.

University of Tübingen, a leading member of Cyber Valley, Europe’s largest Artificial Intelligence research consortium and Boehringer Ingelheim launch an AI and data science fellowship program for top talents from around the world.

AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, provided a business update and the outcome from its pre-planned 400-patient interim futility analysis for the pivotal phase 3 REVIVAL study, which has been stopped for futility based on the study’s primary endpoint.

Immuneering Corporation announced the appointment of Leah R. Neufeld to the newly created position of Chief People Officer, effective immediately.